SCHEMBL6084598

SCHEMBL6084598

O=C(Nc1ccc(-c2n[nH]cc2-c2nc3cc4ccccc4cc3o2)cc1)c1ccccc1F

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 13/20 0.62
THRB P10828 2/20 0.60
RAB9A P51151 7/20 0.59
NPC1 O15118 6/20 0.59
KMT2A Q03164 3/20 0.59
MEN1 O00255 1/20 0.59
KDM4E B2RXH2 7/20 0.57
ALDH1A1 P00352 6/20 0.57
HPGD P15428 5/20 0.57
TP53 P04637 5/20 0.57
HSD17B10 Q99714 3/20 0.57
SMN1; SMN2 Q16637 4/20 0.56
RXFP1 Q9HBX9 3/20 0.54
POLB P06746 3/20 0.54
NPSR1 Q6W5P4 3/20 0.53
GLA P06280 1/20 0.53
LMNA P02545 1/20 0.47
NFKB1 P19838 1/20 0.47
NFKB2 Q00653 1/20 0.47
RELA Q04206 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6086443 0.89 MAPT (0.52) MAPTTHRBRAB9ANPC1KMT2A
SCHEMBL6086965 0.88 MAPT (0.61) MAPTTHRBRAB9ANPC1KMT2A
SCHEMBL6086180 0.87 MAPT (0.48) MAPTTHRBRAB9ANPC1KMT2A
SCHEMBL6084692 0.87 MAPT (0.46) MAPTTHRBRAB9ANPC1KMT2A
SCHEMBL6084108 0.85 MAPT (0.52) MAPTTHRBKDM4ETP53SMN1; SMN2
SCHEMBL6085202 0.83 MAPT (0.48) MAPTTHRBRAB9ANPC1KMT2A
SCHEMBL6085902 0.83 SMN1; SMN2 (0.49) MAPTTHRBRAB9ANPC1KMT2A
SCHEMBL6083913 0.83 MAPT (0.48) MAPTTHRBRAB9ANPC1KMT2A
SCHEMBL6084211 0.82 TP53 (0.49) MAPTTHRBRAB9ANPC1KDM4E
SCHEMBL6084107 0.82 UTRN (0.49) MAPTTHRBRAB9ANPC1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US claimed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP claimed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US claimed
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US disclosed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP disclosed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors MAP3K15, MAP3K20, MAP3K3 MAPT 801/4885THRB 1963/4885RAB9A 2584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.